Exact Sciences CorpNASDAQ:EXAS
- LAST PRICE49.5200
- TODAY'S CHANGE (%)0.1900 (0.3852%)
- Bid / Lots49.4700/ 7
- Ask / Lots49.5700/ 4
- Open / Previous Close48.9800 / 49.3300
- Day Range
- 52 Week Range
- Volume177,009
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EXAS |
|---|---|---|
| 09:32 ET | 23125 | 49.04 |
| 09:33 ET | 3756 | 49.37 |
| 09:35 ET | 8414 | 49.63 |
| 09:37 ET | 9531 | 49.85 |
| 09:39 ET | 13856 | 49.745 |
| 09:42 ET | 4627 | 49.705 |
| 09:44 ET | 8636 | 49.495 |
| 09:46 ET | 5726 | 49.4552 |
| 09:48 ET | 6172 | 49.2636 |
| 09:50 ET | 5512 | 49.45 |
| 09:51 ET | 15440 | 49.49 |
| 09:53 ET | 3651 | 49.425 |
| 09:55 ET | 711 | 49.51 |
| 09:57 ET | 8306 | 49.3551 |
| 10:00 ET | 17516 | 49.43 |
| 10:02 ET | 4576 | 49.52 |
Nov 13, 2024
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy, from 1:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
1:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 11, 2024
DJ Exact Sciences Is Maintained at Overweight by Piper Sandler, from 8:04AM ET on Monday Nov 11, 2024 by Dow Jones
8:04AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 6, 2024
DJ Exact Sciences Is Maintained at Buy by Citigroup, from 2:07PM ET on Wednesday Nov 06, 2024 by Dow Jones
2:07PM ET on Wednesday Nov 06, 2024 by Dow JonesDJ Exact Sciences Is Maintained at Buy by Jefferies, from 1:41PM ET on Wednesday Nov 06, 2024 by Dow Jones
1:41PM ET on Wednesday Nov 06, 2024 by Dow JonesDJ Exact Sciences Down Over 23%, on Pace for Largest Percent Decrease Since October 2015 -- Data Talk, from 1:19PM ET on Wednesday Nov 06, 2024 by Dow Jones
1:19PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Exact Sciences Corp | 9.1B | -42.3x | --- |
Qiagen NV | 9.2B | 100.3x | +12.66% |
BioMarin Pharmaceutical Inc | 12.1B | 37.9x | --- |
Medpace Holdings Inc | 9.7B | 26.5x | +35.10% |
Exelixis Inc | 9.8B | 22.0x | -21.77% |
Neurocrine Biosciences Inc | 11.9B | 31.4x | +62.04% |
Company Information
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Contact Information
- Headquarters
- 5505 Endeavor LaneMADISON, WI, United States 53719
- Phone
- 608-284-5700
- Fax
- 608-284-5701
Executives
- Chairman of the Board, President, Chief Executive Officer
- Kevin Conroy
- Chief Financial Officer
- Aaron Bloomer
- Executive Vice President, General Manager - Precision Oncology
- Brian Baranick
- Executive Vice President, General Manager - Screening
- Jacob Orville
- Executive Vice President - Human Resources
- Sarah Condella
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.1B |
|---|---|
Revenue (TTM) | $2.7B |
Shares Outstanding | 185.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.17 |
Book Value | $17.34 |
P/E Ratio | -42.3x |
Price/Sales (TTM) | 3.4 |
Price/Cash Flow (TTM) | 5,008.1x |
Operating Margin | -8.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
